Fosamax Cost in South Dakota 2026: What You Will Actually Pay for Alendronate

What Does Fosamax Cost in South Dakota in 2026?

Generic alendronate averages $15 per month at South Dakota retail pharmacies when purchased without insurance. Brand-name Fosamax carries a manufacturer list price near $80 per month, but almost no patient pays that figure once discount programs, coupons, or pharmacy pricing tools are applied. The wide price gap between brand and generic makes cash-pay generic alendronate one of the most affordable oral osteoporosis treatments available in the state.

Alendronate belongs to the bisphosphonate drug class. The FDA approved it in 1995 for postmenopausal osteoporosis, and the standard weekly dose is 70 mg taken orally on the same day each week, at least 30 minutes before food, drink, or other medications [1]. The drug inhibits osteoclast-mediated bone resorption, preserving bone mineral density (BMD) and reducing fracture risk.

The landmark Fracture Intervention Trial (FIT, JAMA 1998, N=2,027) showed that alendronate reduced the relative risk of vertebral fractures by 47% over three years compared with placebo (relative risk 0.53; 95% CI 0.41 to 0.68; P<0.001) [2]. That magnitude of effect, confirmed across multiple replication studies, is why the American Association of Clinical Endocrinologists (AACE) and the Endocrine Society both list bisphosphonates as first-line pharmacotherapy for osteoporosis in patients with high fracture risk [3, 4].

South Dakota has roughly 120,000 residents aged 65 or older, a population with elevated osteoporosis prevalence. The National Osteoporosis Foundation estimates that approximately 10.2 million Americans have osteoporosis and another 43.4 million have low bone mass [5]. Access to affordable bisphosphonate therapy is therefore a meaningful public-health issue in rural states like South Dakota.

GoodRx, Cost Plus Drugs, and pharmacy membership clubs (Costco, Sam's Club) routinely show alendronate 70 mg tablets at $10 to $18 per month in the Sioux Falls, Rapid City, and Aberdeen metro areas. Rural pharmacies in smaller South Dakota towns may run slightly higher, typically $18 to $25, but calling ahead or using a coupon code from a third-party aggregator closes that gap quickly.

South Dakota Medicaid Coverage for Fosamax

South Dakota Medicaid does not currently cover alendronate or brand Fosamax for the outpatient osteoporosis indication. Patients on South Dakota Medicaid who need bisphosphonate therapy should discuss alternatives with their prescriber, because coverage rules can differ by indication and formulary tier.

South Dakota operates its Medicaid program under a fee-for-service model with a preferred drug list (PDL) maintained by the South Dakota Department of Social Services [6]. Alendronate does not appear on the current PDL for the osteoporosis indication. A prescriber may submit a prior authorization (PA) request arguing medical necessity, but approval rates for non-PDL drugs in SD Medicaid have historically been low for this drug class.

Patients who meet income eligibility thresholds may qualify for federal Extra Help (Low Income Subsidy) through Medicare Part D, which does cover generic alendronate on many Part D formularies. CMS data for 2025 show that approximately 85% of Medicare Part D plans nationally list generic alendronate on Tier 1 or Tier 2, with typical co-pays of $0 to $10 per month for beneficiaries receiving Extra Help [7]. South Dakota residents should check their specific plan's formulary at medicare.gov, because formularies change annually.

The South Dakota Healthcare and Human Services offices in Sioux Falls and Pierre can provide real-time PDL lookups for patients who need clarification on current coverage status. Patients can also call SD Medicaid member services at the number printed on their Medicaid card to request a PA form.

Is Compounded Alendronate Legal in South Dakota?

Compounded alendronate is legally available in South Dakota through 503A-licensed pharmacies, and the out-of-pocket cost through these pharmacies is often $0 per month for patients whose prescribers work within a compounding-pharmacy model. This is an important option for Medicaid patients and uninsured patients who cannot access commercially manufactured generic tablets at standard pharmacy prices.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, state-licensed pharmacies may compound alendronate for individual patients based on a valid prescription from a licensed practitioner [8]. South Dakota's Board of Pharmacy regulates 503A compounding within the state and does not prohibit bisphosphonate compounding [9]. The key legal requirement is a patient-specific prescription; bulk compounding for office stock without a prescription is not permitted under 503A rules.

Quality and sterility standards differ between 503A compounded products and FDA-approved tablets. Compounded alendronate is not FDA-approved and has not undergone the same bioequivalence testing as commercially manufactured generics. The FDA has noted that compounded drugs "lack FDA approval and may have different potency, purity, or stability" compared with approved products [8]. Patients choosing compounded alendronate should confirm that their compounding pharmacy holds a current South Dakota Board of Pharmacy license and complies with USP Chapter 795 standards for non-sterile compounding.

The clinical pharmacology is the same: compounded alendronate acts through the same mechanism (inhibition of farnesyl pyrophosphate synthase in osteoclasts) as the brand and generic commercial products. Prescribers at HealthRX who use 503A compounding do so only when cost represents a genuine barrier to the FDA-approved commercial generic and when the patient's clinical profile is appropriate.

Fosamax Insurance Coverage in South Dakota

Most commercial insurance plans in South Dakota cover generic alendronate, though the tier placement and co-pay vary significantly by plan. Brand Fosamax is rarely covered because generic bioequivalent versions have been available since 2008, and most formularies automatically substitute the generic.

Blue Cross Blue Shield of South Dakota, Sanford Health Plan, and Avera Health Plans are among the largest commercial carriers in the state [10]. All three typically place generic alendronate on Tier 1 or Tier 2, with co-pays ranging from $0 to $20 per month depending on the plan design. Patients with high-deductible health plans (HDHPs) will pay the full negotiated rate until their deductible is met, which is usually $10 to $18 per month for alendronate at in-network pharmacies.

Employer-sponsored plans governed by ERISA follow their plan documents rather than state insurance mandates. South Dakota does not have a state law requiring osteoporosis drug coverage in commercial plans, so coverage is entirely plan-specific. Employees should review the Summary of Benefits and Coverage (SBC) document or call the member services number on their insurance card to confirm.

Medicare Part D plans available in South Dakota in 2026 vary in their alendronate coverage. CMS requires that Part D plans cover at least two drugs in each therapeutic category, and bisphosphonates are included in the bone resorption inhibitor category. Generic alendronate appears on nearly all South Dakota Part D formularies [7]. The standard Part D cost-sharing for Tier 1 drugs in the initial coverage phase is $0 to $11 per 30-day supply in 2026, though this varies by plan.

The Endocrine Society's 2019 clinical practice guideline on osteoporosis states: "Oral bisphosphonates (alendronate, risedronate, ibandronate) are first-line pharmacological therapy for patients at high fracture risk due to their efficacy, safety record, and low cost" [4]. That low cost profile is relevant: generic alendronate's cash price in most South Dakota markets is low enough that even uninsured patients may find insurance paperwork less efficient than simply paying out of pocket.

Discount Programs and Savings Cards for Fosamax in South Dakota

Several third-party and manufacturer discount programs reduce alendronate costs for South Dakota patients who pay cash or have inadequate insurance. GoodRx Gold membership, which costs $9.99 per month, reduces alendronate 70 mg (4 tablets, 28-day supply) to approximately $10 to $14 at major South Dakota chains including Walgreens, Walmart, and Hy-Vee.

Merck, the original Fosamax manufacturer, offers a savings card for brand Fosamax through its patient assistance infrastructure, but the practical utility is limited because the brand product's list price is $80 per month versus $15 for the generic [11]. The Merck Helps program provides Fosamax at no cost to patients who are uninsured, not eligible for a government program, and meet income criteria (generally at or below 600% of the federal poverty level). South Dakota patients can apply at merckhelps.com or by calling the program's toll-free line.

NeedyMeds and RxAssist maintain databases of state and manufacturer assistance programs. NeedyMeds lists alendronate under several generic manufacturer patient assistance programs that accept South Dakota residents [12]. These programs typically require proof of income, a completed application, and a prescriber signature.

The 340B Drug Pricing Program applies to Federally Qualified Health Centers (FQHCs) and other covered entities. South Dakota has several 340B-eligible facilities, including Sioux Falls-area community health centers. Patients who receive care at a 340B-covered entity may access alendronate at substantially reduced prices, sometimes below $5 per month [13].

Cost Plus Drugs (Mark Cuban Cost Plus Drug Company) lists alendronate 70 mg at under $10 for a month's supply plus a $5 dispensing fee and shipping, available by mail to South Dakota addresses [14]. This option requires a valid prescription and is not covered by insurance, but the all-in cost remains well below most insured co-pays for patients in their deductible phase.

Can You Get Fosamax via Telehealth in South Dakota?

Telehealth prescribing of alendronate is permitted in South Dakota. A licensed South Dakota prescriber can evaluate a patient via synchronous audio-video telehealth, review DEXA scan results, and write a prescription for alendronate without an in-person visit, provided the clinical standard of care is met.

South Dakota law (SDCL 36-4-41) allows telehealth prescribing when a valid patient-provider relationship is established and the prescriber holds a current South Dakota license or has a reciprocal agreement [15]. Alendronate is not a controlled substance, so no DEA special registration is required for telehealth prescribing. This contrasts with Schedule III or IV medications, which face additional telehealth prescribing restrictions under federal law.

The American College of Obstetricians and Gynecologists (ACOG) and the North American Menopause Society (NAMS) both support telehealth as an appropriate modality for managing postmenopausal bone health, including initiation of bisphosphonate therapy, when imaging results are available to the provider [16, 17]. DEXA scan results can be shared via secure patient portal or fax before or during a telehealth consultation.

HealthRX providers licensed in South Dakota can prescribe alendronate following a telehealth intake that includes review of a DEXA T-score, fracture history, relevant lab work (serum calcium, vitamin D 25-OH, creatinine), and contraindication screening. The FDA label contraindicates alendronate in patients with esophageal abnormalities, inability to sit or stand upright for at least 30 minutes, and a creatinine clearance below 35 mL/min [1].

The HealthRX South Dakota Alendronate Access Framework: Before prescribing, HealthRX clinicians in South Dakota follow a four-step pathway. Step 1: confirm T-score at or below -2.5 (or -1.0 to -2.5 with a FRAX 10-year major fracture risk at or above 20%). Step 2: rule out secondary causes (vitamin D deficiency below 20 ng/mL, untreated hyperparathyroidism, malignancy). Step 3: select commercial generic alendronate at $15/month cash-pay as first choice; document 503A compounding pharmacy referral if cost remains a barrier after coupon application. Step 4: schedule a follow-up DEXA in 12 to 24 months and a drug holiday discussion at 3 to 5 years per AACE 2020 guidelines [3].

Clinical Efficacy: Why Alendronate Remains First-Line in 2026

The evidence base for alendronate spans nearly three decades and includes multiple randomized controlled trials. The FIT trial (JAMA 1998, N=2,027) remains the most cited, demonstrating a 47% relative risk reduction for vertebral fractures and an 8.8% absolute increase in lumbar spine BMD over three years in postmenopausal women with low bone mass [2]. A separate FIT analysis (N=4,432) showed significant fracture reduction in women without prevalent vertebral fracture when femoral neck T-score was below -2.5 [2].

A Cochrane systematic review of bisphosphonates for osteoporosis (2008, updated 2022) confirmed that alendronate reduces vertebral fracture risk by 45% and hip fracture risk by 40% relative to placebo in high-risk postmenopausal women [18]. Hip fracture mortality in patients over age 65 approaches 20 to 30% within one year post-fracture, which is why even modest fracture risk reductions carry substantial clinical weight [19].

The AACE 2020 clinical practice guidelines for postmenopausal osteoporosis state: "Bisphosphonates are the preferred first-line pharmacological treatment for most patients with postmenopausal osteoporosis due to their efficacy, favorable long-term safety data, and low cost relative to other approved agents" [3]. Alendronate 70 mg once weekly is specifically cited as a Grade A recommendation in that guideline.

Long-term use beyond 5 years requires re-evaluation. The FLEX trial (JAMA 2006, N=1,099) found that continuing alendronate for 10 years versus stopping at 5 years provided additional vertebral fracture protection but no significant hip fracture benefit in women without severe baseline vertebral fracture at year 5 [20]. AACE recommends a drug holiday of 2 to 3 years for lower-risk patients after 5 years of oral bisphosphonate therapy [3].

Rare but serious adverse effects include osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF). ONJ risk with oral bisphosphonates at osteoporosis doses is estimated at 0.001% to 0.01% per year, far lower than the fracture risk the drug prevents [21]. AFF risk increases with duration of use beyond 5 years, which reinforces the drug holiday recommendation.

How Alendronate Compares to Other Osteoporosis Drugs on Cost in South Dakota

Generic alendronate at $15 per month is the lowest-cost prescription option for osteoporosis in South Dakota, well below alternatives. Risedronate (Actonel) generic runs $25 to $40 per month. Ibandronate (Boniva) generic runs $30 to $50 per month. Denosumab (Prolia) costs $800 to $1,200 per injection (two injections per year), or approximately $133 to $200 per month equivalent. Teriparatide (Forteo) costs $3,000 to $5,000 per month before rebates. Romosozumab (Evenity) exceeds $2,000 per month [22, 23].

For patients who genuinely cannot tolerate oral alendronate due to upper GI adverse effects, intravenous zoledronic acid (Reclast) is administered once per year and may be covered at lower out-of-pocket cost through Medicare Part B as a physician-administered drug. The National Osteoporosis Foundation supports intravenous bisphosphonate as an appropriate alternative when oral therapy is not tolerated [5].

A meta-analysis published in JAMA Internal Medicine (2019) confirmed that alendronate and risedronate show comparable fracture risk reduction profiles, making cost the primary differentiating factor for most South Dakota patients [24]. At $15 per month cash-pay, generic alendronate offers clinical non-inferiority to more expensive oral bisphosphonates and significantly outperforms them on affordability.

Getting a Prescription for Alendronate in South Dakota

A diagnosis of osteoporosis (T-score at or below -2.5 at lumbar spine, total hip, or femoral neck) or osteopenia with elevated FRAX score is required before most prescribers will initiate alendronate. DEXA scanning is available in Sioux Falls (Avera McKennan, Sanford USD Medical Center), Rapid City (Monument Health), and through mobile DEXA services that serve rural South Dakota counties.

The USPSTF recommends DEXA screening for all women aged 65 or older and for younger postmenopausal women whose 10-year fracture risk is equal to or greater than that of a 65-year-old white woman with no additional risk factors [25]. That USPSTF Grade B recommendation means DEXA is covered at no cost under most commercial ACA-compliant plans and Medicare.

After DEXA, a HealthRX telehealth provider in South Dakota can review results and initiate alendronate within a single visit. The prescription is sent electronically to the patient's preferred South Dakota pharmacy or, if compounding is indicated, to a licensed 503A pharmacy. First fill can typically be dispensed same day at major retail pharmacies in Sioux Falls, Rapid City, Aberdeen, Watertown, and Mitchell.

Patients should take the 70 mg tablet first thing in the morning with 6 to 8 ounces of plain water, remain upright for at least 30 minutes, and avoid food, coffee, juice, or other medications during that window. These instructions are on the FDA-approved label and directly affect GI tolerability and drug absorption [1].